GLP-1 medications becoming a $200 billion market by 2030 — This indicates significant growth opportunities for pharmaceutical companies and healthcare providers.
Dramatic increase in GLP-1 usage in the US (from 3% to 11%) — Signals potential changes in obesity treatment strategies and increased demand for related services.
